Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program

Archives of Internal Medicine

Volumn 160, Issue 7, 2000, Pages 953-958

  Ernster, Virginia L ^a   Barclay, John ^a   Kerlikowske, Karla ^a,b   Wilkie, Heather ^a   Ballard Barbash, Rachel ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0034630285     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.7.953     Document Type: Article

References (26)

1. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson IC. Incidence and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275:913-918.
2. Surveillance, Epidemiology and End Results (SEER) Program [data on public use CD-ROM (1973-1993)]. Bethesda, Md: National Cancer Institute, Division of Cancer Prevention and Control Surveillance Program, Cancer Statistics Branch; 1996.
3. Ernster VL. Epidemiology and natural history of ductal carcinoma in situ. In: Silverstein MJ, ed. Ductal Carcinoma In Situ of the Breast. Baltimore, Md: Williams & Wilkins; 1997:23-33.
4. May DS, Lee NC, Nadel MR, et al. The National Breast and Cervical Cancer Early Detection Program: report on the first 4 years of mammography provided to medically underserved women. Am J Roentgenol. 1998;170:97-104.
5. Page DL, Jensen RA. Ductal carcinoma in situ of the breast: understanding the misunderstood stepchild. JAMA. 1996;275:948-949.
6. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997;127:1023-1028.
7. Sneige N, McNeese MD, Atkinson EN, et al. Ductal carcinoma in situ treated with lumpectomy and irradiation: histopathological analysis of 49 specimens with emphasis on risk factors and long-term results. Hum Pathol. 1995;26:642-649.
8. White J, Levine A, Gustafson G, et al. Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy. Int J Radiat Oncology Biol Phys. 1995;31:791-797.
9. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996;14:754-763.
10. Silverstein MJ, Lagios MD, Martino S, et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol. 1998; 16:1367-1373.
11. Habel LA, Daling JR, Newcomb PA, et al. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 1998;7:689-696.
12. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993-2000.
13. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol 1. Lyon, France: International Agency for Research on Cancer; 1980.
14. Swanson GM, Ragheb NE, Lin C-S, et al. Breast cancer among black and white women in the 1980s. Cancer. 1993;72:788-798.
15. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston, Mass: Little Brown & Co Inc; 1991.
16. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med. 1980;303:1038-1041.
17. Horwitz R, Viscoll CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336:542-545.
18. Lee JR-J, Vogel VG. Who uses screening mammography regularly? Cancer Epidemiol Biomarkers Prev. 1995;4:901-906.
19. Hofer TP, Katz SJ. Healthy behaviors among women in the United States and Ontario: the effect on use of preventive care. Am J Public Health. 1996;86:1755-1759.
20. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991;115:455-456.
21. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
22. Grodstein F, Stampfer MD, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-1775.
23. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
24. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med. 1997;336:611-617.
25. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women. JAMA. 1996;276:1404-1408.
26. Neugat AI, Rosenberg DJ, Ahsan H, et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev. 1998;7:869-873.